The financing was led by Presight Capital, with participation from a new investor syndicate including Founders Fund as well as from existing investor Peter Thiel. The proceeds of the financing will be used to expand Peptilogics' computational platform and invest in technologies to improve its drug design engine, as well as accelerate development of a pipeline of peptide therapeutics including the Company's lead clinical asset, PLG0206, which has demonstrated first-in-class safety and best-in-class efficacy.

Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics. Through their computational platform, Peptilogics is radically altering drug discovery by not only uncovering new, previously unexplored chemical design space, but ensuring that each potential therapeutic is biologically viable and scalable to manufacture. Peptilogics' lead clinical stage peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections, an unmet medical need. More information on Peptilogics can be found at www.peptilogics.com as well as on Twitter and LinkedIn.